Mersana Therapeutics, Inc. (NASDAQ:MRSN) is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) for cancer treatment. The company aims to improve the lives of patients with cancer by creating innovative therapies. Mersana operates in a competitive landscape alongside companies like Kura Oncology, MacroGenics, Syndax Pharmaceuticals, Deciphera Pharmaceuticals, and Scholar Rock Holding Corporation.
In evaluating Mersana's financial efficiency, the Return on Invested Capital (ROIC) is a critical metric. Mersana's ROIC is -275.91%, which is significantly lower than its Weighted Average Cost of Capital (WACC) of 7.09%. This results in a ROIC to WACC ratio of -38.90, indicating that Mersana is not generating returns that exceed its cost of capital.
Comparatively, Kura Oncology has a ROIC of -45.39% and a WACC of 4.79%, leading to a ROIC to WACC ratio of -9.48. This suggests that while Kura also struggles with negative returns, it is more efficient than Mersana in managing its capital costs. Similarly, MacroGenics, with a ROIC of -49.77% and a WACC of 8.83%, achieves a ROIC to WACC ratio of -5.64, the highest among the peers, indicating better capital management.
Syndax Pharmaceuticals and Deciphera Pharmaceuticals also face challenges with negative ROICs of -66.59% and -56.11%, respectively. Their ROIC to WACC ratios of -11.94 and -10.89 reflect inefficiencies, though they are still more favorable compared to Mersana. Scholar Rock, with a ROIC of -101.98% and a WACC of 6.68%, has a ROIC to WACC ratio of -15.26, showing significant inefficiency but still better than Mersana.
Overall, the analysis reveals that Mersana Therapeutics has the lowest ROIC to WACC ratio among its peers, highlighting its struggle to generate returns over its cost of capital. Despite the challenges faced by all companies in this sector, MacroGenics stands out with the highest ROIC to WACC ratio, indicating relatively better performance in managing capital costs.
